Why continued surveillance? Intermittent blood pressure and heart rate abnormality under treatment

• Published in: Biomedicine & pharmacotherapy Vol. 59; no. Suppl 1; pp. S141 - S151
• Main Authors: Katinas, G.S., Cornélissen, G., Otsuka, K., Haus, E., Bakken, E.E., Halberg, F.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Paris Elsevier SAS 01.10.2005; Elsevier
• Subjects: Adult; Antihypertensive Agents - therapeutic use; Biological and medical sciences; Blood pressure; Blood Pressure - drug effects; Blood Pressure - physiology; Circadian Rhythm - physiology; Heart rate; Heart Rate - drug effects; Heart Rate - physiology; Humans; Hypertension - drug therapy; Hypertension - physiopathology; Male; Medical sciences; Monitoring, Physiologic; Periodicity; Pharmacology. Drug treatments; Risk Factors; Surveillance; Heart rate; Surveillance; Blood pressure; Treatment; Intermittent; Toxicity; Arterial pressure; Hemodynamics
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/S0753-3322(05)80022-8

Several opinion leaders have monitored their blood pressure systematically a sufficient number of times a day for chronomic (time structural) analyses, from the time of encountering chronobiology until their death; they set an example for others who also may not wish to base treatment on single spotchecks in a health care office. Such self-measurements, while extremely helpful, were not readily feasible without a noteworthy interruption of activities during waking as well as of sleep. New, relatively unobtrusive instrumentation now makes monitoring possible and cost-effective and will save lives. Illustrative results and problems encountered in an as-one-goes self-survey by GSK, a physician-scientist, are presented herein. Both MESOR-hypertension and CHAT (circadian hyper-amplitude-tension) can be intermittent conditions even under treatment, and treatment is best adjusted based on monitoring, rather than “flying blind”.